These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23564665)

  • 1. Deriving time discounting correction factors for TTO tariffs.
    Attema AE; Brouwer WB
    Health Econ; 2014 Apr; 23(4):410-25. PubMed ID: 23564665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead time TTO: leading to better health state valuations?
    Attema AE; Versteegh MM; Oppe M; Brouwer WB; Stolk EA
    Health Econ; 2013 Apr; 22(4):376-92. PubMed ID: 22396243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of correcting values: influence and importance of correcting TTO scores for time preference.
    Attema AE; Brouwer WB
    Value Health; 2010 Dec; 13(8):879-84. PubMed ID: 20659269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correction of TTO-scores for utility curvature using a risk-free utility elicitation method.
    Attema AE; Brouwer WB
    J Health Econ; 2009 Jan; 28(1):234-43. PubMed ID: 19062114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Would you rather be ill now, or later?
    Attema AE; Versteegh MM
    Health Econ; 2013 Dec; 22(12):1496-506. PubMed ID: 23229912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correcting biases in standard gamble and time tradeoff utilities.
    van Osch SM; Wakker PP; van den Hout WB; Stiggelbout AM
    Med Decis Making; 2004; 24(5):511-7. PubMed ID: 15359000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health.
    Lugnér AK; Krabbe PFM
    Expert Rev Pharmacoecon Outcomes Res; 2020 Aug; 20(4):331-342. PubMed ID: 32552002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?
    Boye KS; Matza LS; Feeny DH; Johnston JA; Bowman L; Jordan JB
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):437-50. PubMed ID: 24832003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of subjective life expectancy on health state valuations using a 10 year TTO.
    van Nooten FE; Koolman X; Brouwer WB
    Health Econ; 2009 May; 18(5):549-58. PubMed ID: 18702082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double discounting of QALYs.
    MacKeigan LD; Gafni A; O'Brien BJ
    Health Econ; 2003 Feb; 12(2):165-9. PubMed ID: 12563665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury.
    Lin MR; Yu WY; Wang SC
    Arch Phys Med Rehabil; 2012 Feb; 93(2):245-52. PubMed ID: 22289233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elicitation of health state utilities associated with differing durations of morning stiffness in rheumatoid arthritis.
    Iqbal I; Dasgupta B; Taylor P; Heron L; Pilling C
    J Med Econ; 2012; 15(6):1192-200. PubMed ID: 22804691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of social care for adults: developing a preference-weighted measure.
    Netten A; Burge P; Malley J; Potoglou D; Towers AM; Brazier J; Flynn T; Forder J; Wall B
    Health Technol Assess; 2012; 16(16):1-166. PubMed ID: 22459668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new explanation for the difference between time trade-off utilities and standard gamble utilities.
    Bleichrodt H
    Health Econ; 2002 Jul; 11(5):447-56. PubMed ID: 12112493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we fix it? Yes we can! But what? A new test of procedural invariance in TTO-measurement.
    Attema AE; Brouwer WB
    Health Econ; 2008 Jul; 17(7):877-85. PubMed ID: 18074409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population.
    Kang HJ; Kang E; Jo MW; Park EJ; Yoon S; Lee EK
    Epilepsy Res; 2014 Jul; 108(5):963-71. PubMed ID: 24679945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of methods for converting DCE values onto the full health-dead QALY scale.
    Rowen D; Brazier J; Van Hout B
    Med Decis Making; 2015 Apr; 35(3):328-40. PubMed ID: 25398621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valuing Treatments for Parkinson Disease Incorporating Process Utility: Performance of Best-Worst Scaling, Time Trade-Off, and Visual Analogue Scales.
    Weernink MG; Groothuis-Oudshoorn CG; IJzerman MJ; van Til JA
    Value Health; 2016; 19(2):226-32. PubMed ID: 27021757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
    Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
    Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.